Cargando…

Gamma-Muricholic Acid Inhibits Nonalcoholic Steatohepatitis: Abolishment of Steatosis-Dependent Peroxidative Impairment by FXR/SHP/LXRα/FASN Signaling

Nonalcoholic steatohepatitis (NASH) reflects the outcome of steatosis-based peroxidative impairment. Here, the effect and mechanism of γ-muricholic acid (γ-MCA) on NASH were investigated on the basis of its actions in hepatic steatosis, lipid peroxidation, peroxidative injury, hepatocyte apoptosis,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Yang, Shen, Feng, He, Yafang, Guo, Canjie, Yang, Ruixu, Cao, Haixia, Pan, Qin, Fan, Jiangao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005659/ https://www.ncbi.nlm.nih.gov/pubmed/36904254 http://dx.doi.org/10.3390/nu15051255

Ejemplares similares

Altered DNA Methylation Sites in Peripheral Blood Leukocytes from Patients with Simple Steatosis and Nonalcoholic Steatohepatitis (NASH)
por: Wu, Jiayu, et al.
Publicado: (2018)

Sodium cholate ameliorates nonalcoholic steatohepatitis by activation of FXR signaling
por: Pan, Linyu, et al.
Publicado: (2023)

Dual targeting of hepatocyte DGAT2 and stellate cell FASN alleviates nonalcoholic steatohepatitis in mice
por: Yenilmez, Batuhan, et al.
Publicado: (2023)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis
por: Wattacheril, Julia, et al.
Publicado: (2013)

Mice Abundant in Muricholic Bile Acids Show Resistance to Dietary Induced Steatosis, Weight Gain, and to Impaired Glucose Metabolism
por: Bonde, Ylva, et al.
Publicado: (2016)

FXR controls CHOP expression in steatohepatitis
por: Fuchs, Claudia D., et al.
Publicado: (2017)

Muricholic Acids Inhibit Clostridium difficile Spore Germination and Growth
por: Francis, Michael B., et al.
Publicado: (2013)

Muricholic Acids Promote Resistance to Hypercholesterolemia in Cholesterol-Fed Mice
por: Gaillard, Dany, et al.
Publicado: (2021)

Fermented ginseng, GBCK25, ameliorates steatosis and inflammation in nonalcoholic steatohepatitis model
por: Choi, Naeun, et al.
Publicado: (2019)

Coordinated Actions of FXR and LXR in Metabolism: From Pathogenesis to Pharmacological Targets for Type 2 Diabetes
por: Ding, Lin, et al.
Publicado: (2014)

LXRs, SHP, and FXR in Prostate Cancer: Enemies or Ménage à Quatre With AR?
por: Cariello, Marica, et al.
Publicado: (2018)

Nuclear receptors FXR and SHP regulate protein N-glycan modifications in the liver
por: Mathur, Bhoomika, et al.
Publicado: (2021)

Investigating the Role Intestinal-Specific FXR and SHP in Regulating Lipid Metabolism in Mice
por: Nguyen, James ThienToan, et al.
Publicado: (2021)

Transcriptional Regulation of Metabolic Pathways via Lipid-Sensing Nuclear Receptors PPARs, FXR, and LXR in NASH
por: Cariello, Marica, et al.
Publicado: (2021)

Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis
por: Mendel, Itzhak, et al.
Publicado: (2016)

Dissociation of Intestinal and Hepatic Activities of FXR and LXRα Supports Metabolic Effects of Terminal Ileum Interposition in Rodents
por: Mencarelli, Andrea, et al.
Publicado: (2013)

Steatosis and Steatohepatitis: Complex Disorders
por: Bettermann, Kira, et al.
Publicado: (2014)

Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis
por: Porteiro, Begoña, et al.
Publicado: (2017)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

TTC39B Deficiency Stabilizes LXR Reducing both Atherosclerosis and Steatohepatitis
por: Hsieh, Joanne, et al.
Publicado: (2016)

Metabolic dysfunction-associated fatty liver disease: from basic research to clinical application
por: Yang, Ruixu, et al.
Publicado: (2022)

OR22-01 Sex Differences In Enterohepatic Circulation Mediated By Hepatic FXR And SHP Depletions In Mice
por: Reichardt, Francois, et al.
Publicado: (2023)

FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models
por: O’Farrell, Marie, et al.
Publicado: (2022)

Inhibition of DHCR24 activates LXRα to ameliorate hepatic steatosis and inflammation
por: Zhou, Enchen, et al.
Publicado: (2023)

Berberine Promotes OATP1B1 Expression and Rosuvastatin Uptake by Inducing Nuclear Translocation of FXR and LXRα
por: Liu, Mingyi, et al.
Publicado: (2020)

Pioneer factor Foxa2 enables ligand-dependent activation of type II nuclear receptors FXR and LXRα
por: Kain, Jessica, et al.
Publicado: (2021)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Inhibition of Plasminogen Activator Inhibitor 1 Attenuates Hepatic Steatosis but Does Not Prevent Progressive Nonalcoholic Steatohepatitis in Mice
por: Henkel, Anne S., et al.
Publicado: (2018)

Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis
por: Ferolla, Silvia M., et al.
Publicado: (2016)

The L‐α‐Lysophosphatidylinositol/G Protein–Coupled Receptor 55 System Induces the Development of Nonalcoholic Steatosis and Steatohepatitis
por: Fondevila, Marcos F., et al.
Publicado: (2020)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Adipose Tissue Dysfunction Signals Progression of Hepatic Steatosis Towards Nonalcoholic Steatohepatitis in C57Bl/6 Mice
por: Duval, Caroline, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_8iv85j4l26ni6ul7t9fqgdlii2